CVS Health Co. (NYSE:CVS) Stock Holdings Increased by Marathon Trading Investment Management LLC

Marathon Trading Investment Management LLC raised its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 213.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 43,622 shares of the pharmacy operator's stock after purchasing an additional 29,722 shares during the period. CVS Health accounts for approximately 0.1% of Marathon Trading Investment Management LLC's holdings, making the stock its 25th biggest position. Marathon Trading Investment Management LLC's holdings in CVS Health were worth $1,958,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in CVS. MidAtlantic Capital Management Inc. purchased a new position in shares of CVS Health in the 3rd quarter worth $25,000. Ridgewood Investments LLC increased its stake in CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock worth $28,000 after acquiring an additional 450 shares during the last quarter. Stonebridge Financial Group LLC bought a new stake in shares of CVS Health in the 4th quarter valued at approximately $28,000. Legacy Investment Solutions LLC purchased a new position in shares of CVS Health in the 3rd quarter worth approximately $31,000. Finally, Financial Perspectives Inc increased its position in shares of CVS Health by 137.5% during the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after purchasing an additional 466 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Up 0.5 %

Shares of NYSE:CVS traded up $0.29 on Wednesday, reaching $65.27. The company had a trading volume of 3,497,430 shares, compared to its average volume of 11,606,238. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $82.30 billion, a PE ratio of 17.81, a PEG ratio of 0.98 and a beta of 0.53. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75. The firm's 50 day simple moving average is $57.24 and its 200-day simple moving average is $56.83.

Remove Ads

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 4.08%. CVS Health's dividend payout ratio is currently 72.68%.

Insider Transactions at CVS Health

In related news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael F. Mahoney purchased 30,000 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.24% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on CVS. StockNews.com raised shares of CVS Health from a "sell" rating to a "hold" rating in a research note on Thursday, February 13th. Leerink Partners raised shares of CVS Health from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $55.00 to $75.00 in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised CVS Health from a "hold" rating to a "buy" rating and set a $66.00 target price on the stock in a research note on Tuesday, December 3rd. UBS Group decreased their price target on CVS Health from $62.00 to $59.00 and set a "neutral" rating for the company in a research note on Tuesday, February 11th. Finally, Leerink Partnrs raised CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, CVS Health presently has a consensus rating of "Moderate Buy" and an average target price of $69.83.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.